08 June 2023
As the deputy of Russian Minister of Health Sergey Glagolev says that there is no significant decrease in the number of applications for clinical trials from foreign pharmaceutical companies, despite the fact that numerous manufacturers have withdrawn their applications or terminated the trials that have been started. In addition, there is an increased interest in conducting clinical trials from Russian companies.
“Lately we have seen the unconstructive position of some foreign drug manufacturers by stopping the submission of applications for multicenter clinical trials. Despite such actions, a significant part of foreign companies continue to apply for these permissions,” he said during the XXV All-Russian Conference “PharmMedAppeal-2023”.
Speaking about applications coming from Russian pharmaceutical companies, Glagolev noted that “our industry is starting to explore the cutting edge, such as using orphan drugs in particular”. He also recalled that amendments to the legislation are currently being prepared to be allowed recognition of foreign clinical trials in some cases.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024